IQVIA HOLDINGS INC.
At today's price, IQVIA HOLDINGS INC. (IQV) is priced for +15.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• IQVIA is the dominant data-and-services partner to the drug industry: it runs clinical trials as a contract research organization and sells the prescription and patient data that pharma uses to make decisions, two businesses that feed each other. • The most recent quarter was strong, with revenue up 8.4% to $4.15 billion, R&D net new bookings climbing to $2.5 billion, and the company raising its full-year EPS guidance [Source: IQVIA Q1 2026 earnings release]. • The defining risk is leverage pl
Is IQV overvalued? See what's priced in →
1,036 institutional managers reported holding IQV in 13F filings for the quarter ended 2026-03-31. Together they hold about 89% of the company; the top 10 hold 46%. 97 opened new positions that quarter. Held by Vanguard Group, BlackRock, Harris Associates (Oakmark), among others. On the short side, 5.0M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
IQV has cut its share count 12.1% over the past five years, spending $5.64B on repurchases. It pays no dividend. Cash returned over the past three years: $3.56B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at IQV over the trailing three years: 2024: 1 buy totaling $256k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
IQV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | -2.1% | -10.3% |
| 2023-11-02 | +5.3% | +15.6% |
| 2024-02-16 | +12.2% | -4.4% |
| 2024-05-03 | -4.1% | -6.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
IQV's latest 8-K filings: 2026-06-11 (items 1.01, 2.03, 9.01); 2026-06-04 (items 8.01, 9.01); 2026-06-03 (items 8.01, 9.01); 2026-05-07 (items 8.01, 9.01); 2026-05-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.